Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.
A new study has revealed a crucial link between the TUG1 gene and the ability of cancer cells to proliferate under high-stress conditions. Targeting this gene with a new therapy suppressed tumor ...
Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy. Paclitaxel (PTX) treatment has been identified as a ...
Researchers discovered the mechanism of interaction among TUG1 (red), R-loops (green), and another protein (blue) in cancer cells, which provides a key to therapeutic applications. A new study has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results